VTGN - VistaGen Therapeutics: SAD And MDD Antidepressants May Finally Be Ready To Deliver

• VistaGen has a potentially pivotal Phase 3 trial of its Social Anxiety Disorder ("SAD") treatment PH94B upcoming. The trial is near-identical to its successful Phase 2 trial.
• The neurology specialist has 2 other candidates in development - 1 acquired from the same team that developed PH94B that has also shown efficacy in a P2 trial in MDD.
• The stale antidepressant market lacks a fast-acting treatment, whilst existing therapies also come with undesirable side-effects - meaning VistaGen's assets ought to generate triple-digit-million peak sales, if approved.
• VistaGen management's stewardship since listing the company on the Nasdaq in 2016 appears questionable, with long delays of up to 2 years between trials and failure to develop candidate AV-101.
• The company's shares had been struggling to maintain compliance with Nasdaq listing laws but currently trade at $2. If any of its assets are approved, the consensus is a price target of $6, and I concur.

For further details see: